Radioimmunodetection and radioimmunotherapy of head and neck cancer

Oral Oncology

Volumn 40, Issue 8, 2004, Pages 761-772

  Börjesson, Pontus K E ^a   Postema, Ernst J ^b   De Bree, Remco ^a   Roos, Jan C ^a   Leemans, C René ^a   Kairemo, Kalevi J A ^c   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Molecular imaging; Monoclonal antibodies; Positron emission tomography; Radioimmunoscintigraphy; Radioimmunotherapy; Squamous cell carcinoma

Indexed keywords

MONOCLONAL ANTIBODY;

CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HEAD AND NECK CARCINOMA; HUMAN; ISOTOPE LABELING; LARYNX CARCINOMA; MEDICAL LITERATURE; MOUTH CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARYNX CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; SURGICAL TECHNIQUE; TREATMENT PLANNING;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; NEOPLASM METASTASIS; NEOPLASM STAGING; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY;

EID: 4043052973     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2003.11.009     Document Type: Review

References (84)

1. Vokes E.E., Weichselbaum R.R., Lippman S.M., Hong W.K. Head and neck cancer. New Engl. J. Med. 328:1993;184-194
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer. 94:2001;153-156
3. Leemans C.R., Tiwari R., Nauta J.J.P., van der Waal I., Snow G.B. Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer. 71:1993;452-456
4. Ali S., Tiwari R.M., Snow G.B. False-positive and false-negative neck nodes. Head Neck Surg. 8:1985;78-82
5. van den Brekel M.W.M., Stel H.V., Castelijns J.A., Nauta J.J., van der Waal I., Valk J., et al. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology. 177:1990;379-384
6. van den Brekel M.W.M., Castelijns J.A., Croll G.A., Stel H.V., Valk J., van der Waal I., et al. Magnetic resonance imaging vs palpation of cervical lymph node metastasis. Arch. Otolaryngol. Head Neck Surg. 117:1991;663-673
7. van den Brekel M.W.M., Castelijns J.A., Stel H.V., Luth W.J., Valk J., van der Waal I., et al. Occult metastatic neck disease: detection with US and US-guided fine-needle aspiration cytology. Radiology. 180:1991;457-461
8. Höft S., Muhle C., Brenner W., Sprenger E., Maune S. Fine-needle aspiration cytology of the sentinel lymph node in head and neck cancer. J. Nucl. Med. 43:2002;1585-1590
9. 0 neck in early-stage oral and oropharyngeal squamous cell carcinoma using ultrasonography-guided cytology: is there a role for identification of the sentinel node? Head Neck. 24:2002;282-289
10. Koch W.M., Choti M.A., Civelek A.C., Eisele D.W., Saunders J.R. Gamma probe-directed biopsy of the sentinel node in oral squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 124:1998;455-459
11. 0 neck. Cancer. 91:2001;2077-2083
12. Pitman K.T., Ferlito A., Devaney K.O., Shara A.R., Rinaldo A. Sentinel lymph node biopsy in head and neck cancer. Oral Oncol. 39:2003;343-349
13. Civantos F.J., Gomez C., Duque C., Pedroso F., Goodwin W.J., Weed D.T., et al. Sentinel node biopsy in oral cavity cancer: correlation with PET scan and immunohistochemistry. Head Neck. 25:2003;1-9
14. Nieuwenhuis E.J.C., Jaspars L.H., Castelijns J.A., Bakker B., Wishaupt R.G.A., Denkers F., et al. Quantitative molecular detection of minimal residual head and neck cancer in lymph node aspirates. Clin. Cancer Res. 9:2003;755-761
15. 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur. J. Nucl. Med. 25:1998;1255-1260
16. Kau R.J., Alexiou C., Laubenbacher C., Werner M., Schwaiger M., Arnold W. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch. Otolaryngol. Head Neck Surg. 125:1999;1322-1328
17. Stokkel M.P.C., ten Broek F.W., van Rijk P.P. Preoperative assessment of cervical lymph nodes in head and neck cancer with fluorine-18 fluorodeoxyglucose using a dual-head coincidence camera: a pilot study. Eur. J. Nucl. Med. 26:1999;499-503
18. 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma. Head Neck. 24:2002;345-349
19. 0 neck in oral squamous cell carcinoma: the role of sentinel node biopsy and positron emission tomography. Oral Oncol. 39:2003;350-360
20. 0 oral cavity cancer. Eur. J. Nucl. Med. Mol. Imaging. 30(Suppl 2):2003;S159
21. van den Brekel M.W.M., van der Waal I., Meijer C.J.L.M., Freeman J.L., Castelijns J.A., Snow G.B. The incidence of micrometastases in neck dissection specimens obtained from elective neck dissections. Laryngoscope. 106:1996;987-991
22. Stuckensen T., Kovács A.F., Adams S., Baum R.P. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J. Craniomaxillofac Surg. 28:2000;319-324
23. Greven K.M., Keyes J.W. Jr., Williams D.W., McGuirt W.F., Joyce W.T. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer. 86:1999;114-118
24. Kubota R., Yamada S., Kubota K., Ishiwata K., Tamahashi N., Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J. Nucl. Med. 33:1992;1972-1980
25. Engel H., Steinert H., Buck A., Berthold T., Huch Boni R.A., von Schulthess G.K. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J. Nucl. Med. 37:1996;441-446
26. Dennington M.L., Carter D.R., Meyers A.D. Distant metastases in head and neck epidermoid carcinoma. Laryngoscope. 90:1980;196-201
27. Zbären P., Lehmann W. Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy. Arch. Otolaryngol. Head Neck Surg. 113:1987;762-764
28. Nishijima W., Takooda S., Tokita N., Takayama S., Sakura M. Analyses of distant metastases in squamous cell carcinoma of the head and neck and lesions above the clavicle at autopsy. Arch. Otolaryngol. Head Neck Surg. 119:1993;65-68
29. Teknos T.N., Rosenthal E.L., Lee D., Taylor R., Marn C.S. Positron emission tomography in the evaluation of stages III and IV head and neck cancer. Head Neck. 23:2001;1056-1060
30. Regelink G., Brouwer J., de Bree R., Pruim J., van der Laan B.F.A.M., Vaalburg W., et al. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur. J. Nucl. Med. 29:2002;1024-1030
31. Taneja C., Allen H., Koness R.J., Radie-Keane K., Wanebo H.J. Changing patterns of failure of head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 128:2002;324-327
32. Zuckier L.S., DeNardo G.L. Trials and tribulations: oncological antibody imaging comes to the fore. Semin. Nucl. Med. 27:1997;10-29
33. Hird V., Maraveyas A., Snook D., Dhokia B., Soutter W.P., Meares C., et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer. 68:1993;403-406
34. 2. J. Nucl. Med. 37:1996;1504-1510
35. Behr T.M., Sharkey R.M., Juweid M.E., Dunn R.M., Vagg R.C., Ying Z., et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J. Nucl. Med. 38:1997;858-870
36. Trikha M., Yan L., Nakada M.T. Monoclonal antibodies as therapeutics in oncology. Curr. Opin. Biotechnol. 13:2002;609-614
37. Kretzschmar T., von Rüden T. Antibody discovery: phage display. Curr. Opin. Biotechnol. 13:2002;598-602
38. Kellermann S.A., Green L.L. Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr. Opin. Biotechnol. 13:2002;593-597
39. Hazra D.K., Britton K.E., Lahiri V.L., Gupta A.K., Khanna P., Saran S. Immunotechnological trends in radioimmunotargeting: from 'magic bullet' to 'smart bomb'. Nucl. Med. Commun. 16:1995;66-75
40. Adams G.P., Schier R., McCall A.M., Simmons H.H., Horak E.M., Alpaugh R.K., et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 61:2001;4750-4755
41. Verel I., Heider K.H., Siegmund M., Ostermann E., Patzelt E., Sproll M., et al. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int. J. Cancer. 99:2002;396-402
42. 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol. Immunother. 52:2003;576-582
43. Welt S., Divgi C.R., Scott A.M., Garin-Chesa P., Finn R.D., Graham M., et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J. Clin. Oncol. 12:1994;1193-1203
44. Hicklin D.J., Witte L., Zhu Z., Liao F., Wu Y., Li Y., et al. Monoclonal antibody strategies to block angiogenesis. Drug Discovery Today. 6:2001;517-528
45. Posey J.A., Khazaeli M.B., DelGrosso A., Saleh M.N., Lin C.Y., Huse W., et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother. Radiopharm. 16:2001;125-132
46. Santimaria M., Moscatelli G., Viale G.L., Giovannoni L., Neri G., Viti F., et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 9:2003;571-579
47. Tranter R.M., Fairweather D.S., Bradwell A.R., Dykes P.W., Watson-James S., Chandler S. The detection of squamous cell tumours of the head and neck using radio-labelled antibodies. J. Laryngol. Otol. 98:1984;71-74
48. Kairemo K.J.A., Hopsu E.V.M. Imaging of tumours in the parotid region with Indium-111-labeled monoclonal antibody reacting with carcinoembryonic antigen. Acta Oncol. 29:1990;825-830
49. Kairemo K.J.A., Hopsu E.V.M. Imaging of pharyngeal and laryngeal carcinomas with indium-111-labeled monoclonal anti-CEA antibodies. Laryngoscope. 100:1990;1077-1082
50. Timon C.I., McShane D., Hamilton D., Walsh M.A. Head and neck cancer localization with indium labelled carcinoembryonic antigen: a pilot project. J. Otolaryngol. 20:1991;283-287
51. De Rossi G., Maurizi M., Almadori G., Di Giuda D., Paludetti G., Cadoni G., et al. The contribution of immunoscintigraphy to the diagnosis of head and neck tumours. Nucl. Med. Commun. 18:1997;10-16
52. Soo K.C., Ward M., Roberts K.R., Keeling F., Carter R.L., McCready V.R., et al. Radioimmunoscintigraphy of squamous carcinomas of the head and neck. Head Neck Surg. 9:1987;349-352
53. Baum R.P., Adams S., Kiefer J., Niesen A., Knecht R., Howaldt H.P., et al. A novel technetium-99m labeled monoclonal antibody (174H.64) for staging head and neck cancer by immuno-SPECT. Acta Oncol. 32:1993;747-751
54. Heissler E., Grunert B., Barzen G., Fritsche L., Hell B., Felix R., et al. Radioimmunoscintigraphy of squamous cell carcinoma in the head and neck region. Int. J. Oral Maxillofac. Surg. 23:1994;149-152
55. Adamietz I.A., Baum R.P., Schemman F., Niesen A., Knecht R., Saran F., et al. Improvement of radiation treatment planning in squamous-cell head and neck cancer by immuno-SPECT. J. Nucl. Med. 37:1996;1942-1946
56. de Bree R., Roos J.C., Quak J.J., den Hollander W., Snow G.B., van Dongen G.A.M.S. Clinical screening of monoclonal antibodies323/A3 (K931), cSF-25 (K984), and K928 for suitability of targeting tumors in the upper-aerodigestive and respiratory tract. Nucl. Med. Commun. 15:1994;613-627
57. 2. J. Nucl. Med. 35:1994;775-783
58. de Bree R., Roos J.C., Quak J.J., den Hollander W., Snow G.B., van Dongen G.A.M.S. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin. Cancer Res. 1:1995;591-598
59. 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin. Cancer Res. 6:2000;3046-3055
60. 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J. Nucl. Med. 41:2000;1999-2010
61. 186Re-labeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clin. Cancer Res. 8:2002;3401-3406
62. 186Re- labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 9:2003;3961s-3972s
63. Mendelsohn J. Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol. Immunother. 52:2003;342-346
64. Mattes M.J., Griffiths G.L., Diril H., Goldenberg D.M., Ong G.L., Shih L.B. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer. 73:1994;787-793
65. Brakenhoff R.H., Gerretsen M., Knippels E.M.C., van Dijk M., van Essen H., Olde Weghuis D., et al. The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion. J. Cell Biol. 129:1995;1677-1689
66. 2. Cancer Res. 52:1992;2569-2574
67. van Hal N.L., van Dongen G.A.M.S., Rood-Knippels E.M.C., van der Valk P., Snow G.B., Brakenhoff R.H. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous cell carcinoma, recognizes a CD44 isoform. Int. J. Cancer. 68:1996;520-527
68. 2 in patients with head and neck cancer. Clin. Cancer Res. 1:1995;277-286
69. de Bree R., Roos J.C., Plaizier M.A., Quak J.J., van Kamp G.J., den Hollander W., et al. Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients. Br. J. Cancer. 75:1997;1049-1060
70. Wilson C.B., Snook D.E., Dhokia B., Taylor C.V., Watson I.A., Lammertsma A.A., et al. Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and 124iodine in patients with breast cancer. Int. J. Cancer. 47:1991;344-347
71. Larson S.M., Pentlow K.S., Volkow N.D., Wolf A.P., Finn R.D., Lambrecht R.M., et al. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J. Nucl. Med. 33:1992;2020-2023
72. Kairemo K.J. Positron emission tomography of monoclonal antibodies. Acta Oncol. 32:1993;825-830
73. 124I-CDR-grafted humanized A33 monoclonal antibody. J. Nucl. Med. 42:2001;764-769
74. Verel I., Visser G.W.M., Boerman O.C., van Eerd J.E.M., Finn R., Boellaard R., et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother. Radiopharm. 18:2003;655-661
75. 89Zr-labeled monoclonal antibodies. J. Nucl. Med. 44:2003;1271-1281
76. Verel I., Visser G.W.M., Boellaard R., Boerman O.C., van Eerd J., Snow G.B., et al. Zirconium-89 immuno-PET: scouting of yttrium-90-labeled monoclonal antibodies. J. Nucl. Med. 44:2003;1663-1670
77. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 346:1995;336-340
78. Behr T.M., Griesinger F., Riggert J., Gratz S., Behe M., Kaufmann C.C., et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer. 94:2002;1363-1372
79. Paganelli G., Orecchia R., Jereczek-Fossa B., Grana C., Cremonesi M., de Braud F., et al. Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. Eur. J. Nucl. Med. 25:1998;1336-1339
80. Maraveyas A., Stafford N., Rowlinson-Busza G., Stewart J.S., Epenetos A.A. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma. Cancer Res. 55:1995;1060-1069
81. de Bree R., Kuik D.J., Quak J.J., Roos J.C., van den Brekel M.W.M., Castelijns J.A., et al. The impact of tumour volume and other characteristics on uptake of radiolabeled monoclonal antibodies in tumour tissue of head and neck cancer patients. Eur. J. Nucl. Med. 25:1998;1562-1565
82. van Gog F.B., Brakenhoff R.H., Stigter-van Walsum M., Snow G.B., van Dongen G.A.M.S. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. Int. J. Cancer. 77:1998;13-18
83. Milas L., Mason K., Hunter N., Petersen S., Yamakawa M., Ang K., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 6:2000;701-708
84. Bianco C., Tortora G., Bianco R., Caputo R., Veneziani B.M., Caputo R., et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 8:2002;3250-3258